Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019
This is the seventh special EBMT report on the indications for haematopoietic stem cell
transplantation for haematological diseases, solid tumours and immune disorders. Our aim …
transplantation for haematological diseases, solid tumours and immune disorders. Our aim …
Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the writing committee of the American society for apheresis: the …
J Schwartz, A Padmanabhan, N Aqui… - Journal of clinical …, 2016 - Wiley Online Library
The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special
Issue Writing Committee is charged with reviewing, updating, and categorizing indications …
Issue Writing Committee is charged with reviewing, updating, and categorizing indications …
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
JA Snowden, I Sánchez-Ortega… - Bone marrow …, 2022 - nature.com
For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …
Eltrombopag added to standard immunosuppression for aplastic anemia
Background Acquired aplastic anemia results from immune-mediated destruction of bone
marrow. Immunosuppressive therapies are effective, but reduced numbers of residual stem …
marrow. Immunosuppressive therapies are effective, but reduced numbers of residual stem …
[PDF][PDF] Guidelines for the diagnosis and management of adult aplastic anaemia.
SB Killick, N Bown, J Cavenagh… - British journal of …, 2016 - redbook.streamliners.co.nz
1The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth,
2Northern Genetics Service, Newcastle upon Tyne, 3St Bartholomew's Hospital, Barts …
2Northern Genetics Service, Newcastle upon Tyne, 3St Bartholomew's Hospital, Barts …
Somatic mutations and clonal hematopoiesis in aplastic anemia
T Yoshizato, B Dumitriu, K Hosokawa… - … England Journal of …, 2015 - Mass Medical Soc
Background In patients with acquired aplastic anemia, destruction of hematopoietic cells by
the immune system leads to pancytopenia. Patients have a response to immunosuppressive …
the immune system leads to pancytopenia. Patients have a response to immunosuppressive …
How I treat acquired aplastic anemia
A Bacigalupo - Blood, The Journal of the American Society of …, 2017 - ashpublications.org
Acquired severe aplastic anemia (SAA) is a rare hematologic disease associated with
significant morbidity and mortality. Immune destruction of hemopoietic stem cells plays an …
significant morbidity and mortality. Immune destruction of hemopoietic stem cells plays an …
Indications for allo-and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015
This is the sixth special report that the European Society for Blood and Marrow
Transplantation regularly publishes on the current practice and indications for …
Transplantation regularly publishes on the current practice and indications for …
G-csf and gm-csf in neutropenia
HM Mehta, M Malandra, SJ Corey - The Journal of Immunology, 2015 - journals.aai.org
Abstract G-CSF and GM-CSF are used widely to promote the production of granulocytes or
APCs. The US Food and Drug Administration approved G-CSF (filgrastim) for the treatment …
APCs. The US Food and Drug Administration approved G-CSF (filgrastim) for the treatment …
Guidelines on the use of therapeutic apheresis in clinical practice—evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
The American Society for Apheresis (ASFA) JCA Special Issue Writing Committee is
charged with reviewing, updating and categorizating indications for therapeutic apheresis …
charged with reviewing, updating and categorizating indications for therapeutic apheresis …